Gogoro Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Gogoro Inc trades at $2.99 (market cap $65.04M), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 130.4× Gogoro Inc's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GGR | HNGE | |
|---|---|---|
Market Cap | $65.04M | $8.48B |
Volume | 21,493 | 879,799 |
Sector | Consumer Cyclical | Health |
52-Week High | $4.66 | $105.14 |
52-Week Low | $2.20 | $31.17 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $351.48M | $8.10B |
Signals from Pluang's Aura AI — not financial advice
GGR trades at $3.24, up 2.53% with a bullish technical signal despite negative profitability metrics. The company reported $281.48M revenue for 2025 but a net loss of $79.97M, though losses are projected to narrow in 2026. Recent developments include $61.8M in new equity investments and board appointments to strengthen governance. Technical indicators show bullish momentum with support at $3.00.
While technical momentum appears positive, fundamental challenges persist with negative margins and cash flow. The investment case hinges on Gogoro's ability to achieve profitability amid expansion costs. Analyst consensus remains cautious with 100% hold ratings, suggesting investors await clearer profitability signals before committing.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →